Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of mullerian origin

By Berkenblit A.   Tung N.   Kim Y.   Feyler H.   Niloff J.   Berghe K.V.D.   Cannistra S.A.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 486-493

Elsevier

Access to resources Recommend Favorite

Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?

By Pantaleo M.   Di Battista M.   Catena F.   Astorino M.   Saponara M.   Di Scioscio V.   Santini D.   Piazzi G.   Castellucci P.   Brandi G.   Biasco G.  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 5, 2008-05 ,pp. : 625-630

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors

By Li Jian   Gao Jing   Hong Jinlin   Shen Lin  

Future Oncology, Vol. 8, Iss. 5, 2012-05 ,pp. : 617-624

Future Medicine

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC

By            

Oncology Letters, Vol. 3, Iss. 5, 2012-01 ,pp. : 1064-1068

Spandidos Publications

Access to resources Recommend Favorite